# US 2021/0330628 A1 · Pharmaceutical Compositions Comprising Dimethyl Fumarate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330628 A1
- Document ID: US20210330628A1
- Status: Published application
- Kind: A1
- Application number: 17/316,861
- Filed: 2021-05-11
- Published: 2021-10-28
- Earliest claimed: 2013-12-12
- Applicants: Almirall, S.A.
- Inventors: Maria PLANELLS JIMENEZ; Begoña DUARTE LOPEZ; Pere GUIRO COLL
- Web page: https://patentgrep.com/patent/US20210330628A1

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2846: {Poly(meth)acrylates}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.

## Claims

### Claim 1

A pharmaceutical composition in the form of a gastro-resistant tablet, which pharmaceutical composition is enteric-coated and comprises, based on the total weight of the tablet previous to coating:
(a) 20-30 wt. % of dimethyl fumarate;
(b) 25-35 wt. % of a diluent selected from lactose, D-glucose (dextrose), sucrose, fructose, galactose, calcium carbonate, dibasic calcium phosphate, calcium sulphate, magnesium carbonate, isomalt, mannitol, maltitol, sorbitol, xylitol, and mixtures thereof;
(c) 35-45 wt. % of microcrystalline cellulose;
(d) 1-10 wt. % of croscarmellose sodium; and
wherein the dimethyl fumarate is not covered with a gastro-resistant coating.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

A pharmaceutical composition according to claim 1, further comprising (e) at least one glidant.

### Claim 6 (depends on 5)

A pharmaceutical composition according to claim 5, wherein the glidant (e) is selected from calcium phosphate, calcium silicate, powdered cellulose, magnesium silicate, magnesium trisilicate, silicon dioxide, talc, colloidal silica, colloidal anhydrous silica and mixtures thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition according to claim 1, further comprising (f) at least one lubricant.

### Claim 8 (depends on 7)

A pharmaceutical composition according to claim 7, wherein the lubricant (f) is selected from magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, sodium benzoate, potassium benzoate, light mineral oil, hydrogenated vegetable oils, glycerin monostearate, glyceryl behenate, glyceryl palmitostearate, stearic acid, zinc stearate, and mixtures thereof.

### Claim at position 7

9-14. (canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition according to claim 1 comprising, based on the total weight the tablet previous to coating:
(a) 25 wt. % of dimethyl fumarate;
(b) 30 wt. % of lactose;
(c) 40 wt. % of microcrystalline cellulose;
(d) 4 wt. % of croscarmellose sodium;
(e) 0.5 wt. % of at least one glidant;
(f) 0.5 wt. % at least one lubricant.

### Claim at position 9

16-18. (canceled)

### Claim 19 (depends on 5)

A pharmaceutical composition according to claim 5, further comprising (f) at least one lubricant.

### Claim 20 (depends on 6)

A pharmaceutical composition according to claim 6, further comprising (f) at least one lubricant.
